DarioHealth Revenue Rises 6% to $5.3 Million in Third Quarter
Key Facts
DarioHealth reported third-quarter 2026 revenue rose 6% year over year and 3% from the previous quarter to $5.3 million, according to a company statement published via PR Newswire on November 12. Revenue growth coincided with a 15% year-over-year decline in operating loss and a 10% drop in operating expenses, an operational improvement that did not eliminate the company’s operating loss. Chief Executive Erez Raphael said the results “show that our model is working,” citing multi-condition expansion among existing accounts and new agreements with health plans through channel partners. The available statement did not provide reliable confirmation of earnings per share or the extent to which results exceeded analyst estimates. The supplied pricing data also did not include a verifiable source for the share price or its trading range in the previous session.
Gross margin under generally accepted accounting principles was 59% in the third quarter, compared with 60% in the same period of 2025, the company said. In its business-to-business-to-consumer activity, adjusted gross margin, a non-GAAP measure, remained at about 80% for the eleventh consecutive quarter. Operating expenses were $11.2 million, compared with $12.5 million in the third quarter of 2025, but rose from $9.7 million in the second quarter of 2026. This means expenses declined year over year, while increasing sequentially from the second to the third quarter. The company said operating loss declined 15% year over year, without providing the loss amount in dollars in the available materials.
Cash, cash equivalents and short-term deposits totaled $31.2 million on September 30, 2026, according to the statement. On commercial expansion, the company announced it had signed a contract with one of New Jersey’s largest health plans, covering 1.5 million people. It said this was the third statewide health plan it had signed through its Amwell partnership in the twelve months preceding the announcement. It also said it is working with a national health plan client to make GLP-1 treatment available in the client’s member market. The agreements with health plans and expansion of multi-condition services are among the avenues management said support business growth.
DarioHealth said it has more than 180 signed accounts among employers and health plans, and that contracted annual recurring revenue and advanced opportunities totaled $13.1 million. It added that more than 80% of that amount is tied to multi-condition opportunities. The company expects revenue to accelerate at the end of 2026 and continue accelerating through 2027, driven mainly by converting contracted annual recurring revenue into recognized revenue. The drivers it cited include new enterprise clients and multi-condition expansions, including Dario Women and Dario Sleep services. The company scheduled its earnings call for November 12, 2026, at 8:30 a.m. Eastern Time.